Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Serum Institute of India

TOI Health News Morning Briefing| Parents to sue Covishield maker, new COVID variants FLiRT in India, death of young boy after eating noodles, why is menopause misunderstood and more

Parents claim death due to Covishield, to file lawsuit against Serum Institute of India

The Times of India

WHO prequalifies a second malaria vaccine manufactured by Serum Institute of India

WHO prequalifies R21/Matrix-M malaria vaccine to increase access & prevent malaria in children.

The Hindu

WHO recommends Malaria vaccine made by Oxford University and Serum Institute of India

To date, the R21/Matrix-M malaria vaccine has been licensed for use in Ghana, Nigeria and Burkina Faso. Read further on Dynamite News

Dynamite News

From analysis to the latest developments in health,
read the most diverse news in one place.

Explained | Why is a viable dengue vaccine not yet available

The Hindu explains how dengue vaccines are developed, how many vaccines are currently under trial and the prevailing challenges with vaccine research.

The Hindu

Dengue vaccine: India moves closer to getting its first indigenous vaccine

Moving closer to being able to develop the country’s first vaccine against dengue, drug-makers Serum Institute of India and Panacea Biotec have applied to the Indian Council of Medical Research’s (ICMR) call for Expression of Interest’ for collaborative Phase-III clinical trials for indigenous manufacturers.

The Hindu

Matt Hancock was ‘like a headless chicken’, says former vaccines chief

Dr Clive Dix hit out at the former health secretary in a Telegraph article.

The Independent UK

Serum Institute Of India Launches First Made-In-India HPV Vaccine For Cervical Cancer

Chief Executive Officer of Serum Institute of India (SII), Adar Poonawalla, on Tuesday announced the launch of the first made-in-India Human Papillomavirus (HPV) "CERVAVAC" vaccine, for the prevention of cervical cancer. Read full story on Dynamite News:

Dynamite News

Read news from The Economist, FT, and more,
with one subscription

Rising COVID Cases News From China Is Concerning: SII CEO Adar Poonawala, Urges People Not To Panic

Raising concern on the rising COVID-19 cases in neighbouring China, Serum Institute of India (SII) CEO Adar Poonawala on Wednesday asked the people not to panic because of India's "excellent vaccination coverage and track record". Read on for details:

Dynamite News

Cyrus Poonawalla gifts ragpicker-turned-journalist a car after Mid-Day report on her journey

Nashik-based journalist Maya Muktai has been gifted a car by Serum Institute of India head Cyrus Poonawala, a day after a Mid-Day report on her journey from being a ragpicker to a video journalist who represented India at a UN climate conference in 2010, the paper reported on Friday.

Newslaundry

India's COVID vaccinations hit 2 billion, new cases at four-month high

The Indian government's COVID-19 vaccinations hit 2 billion on Sunday, with booster doses underway for all adults, as daily infections hit four-month high, official data showed.

Reuters

Serum Institute of India to launch vaccine to prevent cervical cancer

Drugs Controller General of India’s approval of SII’s anti-cervical cancer vaccine follows the recommendation of the institute’s COVID-19 vaccine in June last year

The Hindu

The hard road for the Novavax vaccine

Novavax now in financial trouble after missing peak vaccinations

Salon

Novavax missed its global moonshot but is angling to win over mRNA defectors

Novavax hitched its wagon to the global coronavirus pandemic. Before most Americans truly grasped the scope of the danger, the small Maryland biotech startup had secured $1.6 billion in U.S. funding for its COVID-19 vaccine. Its moonshot goal: delivering 2 billion shots to the world by mid-2021.

Tribune News Service

Indian vaccine giant Serum plans African plant in global expansion

The Serum Institute of India (SII), the world's biggest vaccine maker, is considering setting up its first manufacturing plant in Africa as it looks to expand globally after its success in selling COVID-19 shots, its CEO told Reuters on Monday.

Reuters

Get all your
news in one place.

100’s of premium titles.
One news app.

The Times of India

Coronavirus vaccine: Adar Poonawalla clarifies Covovax available for everyone above age of 12 years

Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.

The Hindu

COVID-19: Supreme Court upholds individual’s right against forcible vaccination

Bodily autonomy and integrity are protected under Article 21 of the Constitution, holds Supreme Court

The Times of India

Bombay HC: Does SII have policy to buy back surplus vaccine vials?

MUMBAI: Bombay high court on Thursday directed Serum Institute of India (SII) to inform if it has a policy to buy back surplus Covishield vaccine vials.

The Hindu

Price mix-up mars COVID-19 precaution dose roll-out

Some hospitals opt to wait for clarity.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Hindu

₹10-crore compensation sought for vaccine reaction death

Alleged death due to immunogenic response to vaccine

Benzinga

Novavax's COVID-19 Vaccine Scores Green Light In India with First Approval For Adolescents

Novavax Inc's (NASDAQ:NVAX) COVID-19 vaccine has got emergency-use authorization from the Drugs Controller General of India for children aged 12 to 17 years. The authorization is a global first approval in adolescents for the vaccine manufactured and marketed in India by the Serum Institute of India under the brand name Covovax. Novavax said…

The Times of India

SII CEO Adar Poonawalla urges Novak Djokovic to get vaccinated against Covid-19

PUNE: Serum Institute of India CEO Adar Poonawalla on Thursday urged Serbian tennis superstar Novak Djokovic to get vaccinated against COVID-19.

The Hindu

Low-cost HPV vaccine to be available soon

The Serum Institute of India will soon bring out a low-cost indigenous Human Papillomavirus (HPV) vaccine against cervical cancer, Dr. Umesh Shaligram, Executive Director of Serum Institute of India,

The Times of India

Will work for equitable health, says Dr Poonawalla

PUNE: Covishield maker Serum Institute of India (SII)'s founder-owner Dr Cyrus Poonawalla has been named among this year's awardees for Padma Bhushan.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.